Neurology 1999;53:1719
© 1999 American Academy of Neurology
Articles
Clinical outcome of patients with anti-Hu–associated encephalomyelitis after treatment of the tumor
F. Keime-Guibert, MD,
F. Graus, MD,
P. Broët, MD,
R. Reñé, MD,
J. L. Molinuevo, MD,
C. Ascaso, PhD and
J. Y. Delattre, MD
From the Services of Neurology (Drs. Keime-Guibert and Delattre), Hôpital de la Salpêtrière, Paris, and Unité Inserm 495, Hôpital P. Brousse (Dr. Broët), Villejuif, France; and, Services of Neurology (Drs. Graus and Molinuevo), Hospital Clinic, Barcelona, and Ciutat Sanitria Universitria de Bellvitge (Dr. Reñé), l’Hospitalet, Biostatistics Unit (Dr. Ascaso), Universitat de Barcelona, and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS) (Drs. Graus and Ascaso), Spain.
Address correspondence and reprint requests to Dr. Francesc Graus, Service of Neurology, Hospital Clinic. Villarroel 170, Barcelona 08036, Spain; e-mail: graus{at}medicina.ub.es
OBJECTIVE: To evaluate 1) the effect of the tumor treatment on the clinical course of paraneoplastic encephalomyelitis (PEM) with anti-Hu antibodies, 2) the impact of immunotherapy on the tumor evolution, and 3) the outcome of the small cell lung cancer (SCLC) of PEM patients compared with that of patients without PEM.
METHODS: The authors retrospectively analyzed 51 PEM patients (42 with SCLC, 9 with other tumors) who received antineoplastic treatment with (25 patients) or without (26) concomitant immunotherapy. Tumor response was assessed at the end of the antineoplastic treatment. Progression of PEM was defined as a change of at least 1 point in the Rankin scale measured at the onset and at the end of the tumor treatment. To evaluate the outcome of SCLC, 27 PEM patients with SCLC were matched one-to-one with SCLC patients without PEM for age, performance status, tumor stage, and type of antineoplastic treatment.
RESULTS: Thirty-six (70%) patients were neurologically stable at the end of the tumor treatment. In a logistic regression analysis, tumor complete response was the only predictor of PEM stabilization (OR 7.07; 95% CI 1.68 to 29.76; p = 0.006). Immunotherapy did not modify the outcome of the tumor and PEM. Median survival was similar in SCLC patients with and without PEM, but the probability of survival at 30 months was higher in PEM patients with SCLC (OR 5.26; 95% CI 1.0004 to 27.6902; p = 0.03).
CONCLUSIONS: Complete response of the tumor seems to have a favorable influence on the course of paraneoplastic encephalomyelitis (PEM). Concomitant immunotherapy does not adversely affect the tumor outcome. The small cell lung cancer of PEM patients may have a slightly better evolution than that of patients without PEM.
Key words: Anti-Hu–associated encephalomyelitis—Paraneoplastic—Cancer—Small-cell lung cancer.
This article has been cited by other articles:
|
|
|
|
 
H. Sadeghian and S. Vernino
Review: Progress in the management of paraneoplastic neurological disorders
Therapeutic Advances in Neurological Disorders,
January 1, 2010;
3(1):
43 - 52.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Fletcher
A woman with ataxia
BMJ,
January 28, 2009;
338(jan28_3):
b180 - b180.
[Full Text]
|
|
|
|
|
|
|
J. W. de Beukelaar and P. A. S. Smitt
Managing paraneoplastic neurological disorders.
Oncologist,
March 1, 2006;
11(3):
292 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Tschernatsch, E Stolz, M Strittmatter, M Kaps, and F Blaes
Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data
J. Neurol. Neurosurg. Psychiatry,
December 1, 2005;
76(12):
1702 - 1706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Linke, M. Schroeder, T. Helmberger, and R. Voltz
Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis
Neurology,
July 27, 2004;
63(2):
282 - 286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.E. Monstad, L. Drivsholm, A. Storstein, J.H. Aarseth, M. Haugen, B. Lang, A. Vincent, and C.A. Vedeler
Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer
J. Clin. Oncol.,
March 1, 2004;
22(5):
795 - 800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A Douglas and J. Ellershaw
Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer
Palliative Medicine,
October 1, 2003;
17(7):
638 - 639.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Shams'ili, J. Grefkens, B. de Leeuw, M. van den Bent, H. Hooijkaas, B. van der Holt, C. Vecht, and P. Sillevis Smitt
Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients
Brain,
June 1, 2003;
126(6):
1409 - 1418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Amato and M. P. Anderson
Case 38-2001- A 51-Year-Old Woman with Lung Cancer and Neuropsychiatric Abnormalities
N. Engl. J. Med.,
December 13, 2001;
345(24):
1758 - 1765.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Graus, F. Keime-Guibert, R. Rene, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, and J. Y. Delattre
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Brain,
June 1, 2001;
124(6):
1138 - 1148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Barnett, J Prosser, I Sutton, G M Halmagyi, L Davies, C Harper, and J Dalmau
Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody
J. Neurol. Neurosurg. Psychiatry,
February 1, 2001;
70(2):
222 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bataller, F. Graus, A. Saiz, and J. J. Vilchez
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus
Brain,
February 1, 2001;
124(2):
437 - 443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Rojas, F. Graus, F. Keime-Guibert, R. Rene, J. Y. Delattre, J. M. Ramon, J. Dalmau, and J. B. Posner
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
Neurology,
September 12, 2000;
55(5):
713 - 715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
